119 related articles for article (PubMed ID: 9479593)
1. Clinical significance of preoperative serum levels of CA 125 and TAG-72 in ovarian carcinoma.
Gonzalez A; Vizoso F; Vázquez J; Ruibal A; Balibrea JL
Int J Biol Markers; 1997; 12(3):112-7. PubMed ID: 9479593
[TBL] [Abstract][Full Text] [Related]
2. Preoperative CEA and TAG-72 serum levels as prognostic indicators in resectable gastric carcinoma.
González A; Vizoso F; Allende MT; Sánchez MT; Balibrea JL; Ruibal A
Int J Biol Markers; 1996; 11(3):165-71. PubMed ID: 8915712
[TBL] [Abstract][Full Text] [Related]
3. [Value of the TAG-72 (CA 72-4) tumor marker in primary diagnosis of ovarian carcinoma. A comparison with the established CA-125 marker].
Zeimet AG; Guadagni F; Marth C; Amato T; Müller-Holzner E; Huter O; Daxenbichler G; Dapunt O
Geburtshilfe Frauenheilkd; 1995 Apr; 55(4):195-9. PubMed ID: 7789707
[TBL] [Abstract][Full Text] [Related]
4. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
[TBL] [Abstract][Full Text] [Related]
5. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers].
Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J
Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study.
Zorn KK; Tian C; McGuire WP; Hoskins WJ; Markman M; Muggia FM; Rose PG; Ozols RF; Spriggs D; Armstrong DK
Cancer; 2009 Mar; 115(5):1028-35. PubMed ID: 19156927
[TBL] [Abstract][Full Text] [Related]
7. Predictive and prognostic values of cancer-associated serum antigen (CASA) and cancer antigen 125 (CA 125) levels prior to second-look laparotomy for ovarian cancer.
Kierkegaard O; Mogensen O; Mogensen B; Jakobsen A
Gynecol Oncol; 1995 Nov; 59(2):251-4. PubMed ID: 7590482
[TBL] [Abstract][Full Text] [Related]
8. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
Kudoh K; Kikuchi Y; Kita T; Tode T; Takano M; Hirata J; Mano Y; Yamamoto K; Nagata I
Gynecol Obstet Invest; 1999; 47(1):52-7. PubMed ID: 9852392
[TBL] [Abstract][Full Text] [Related]
9. The role of serum CA-125 levels and CA-125 tissue expression positivity in the prediction of the recurrence of stage III and IV epithelial ovarian tumors (CA-125 levels and tissue CA-125 in ovarian tumors).
Gundogdu F; Soylu F; Erkan L; Tatli O; Mavi S; Yavuzcan A
Arch Gynecol Obstet; 2011 Jun; 283(6):1397-402. PubMed ID: 20645105
[TBL] [Abstract][Full Text] [Related]
10. Elevated Preoperative CA125 or CA19-9 in Borderline Ovarian Tumors: Could It Be Suggestive of Advanced Stage or a Poor Prognosis?
Song T; Lee DH; Jung YW; Yun BS; Seong SJ; Choi CH; Lee JW; Bae DS; Kim BG
Gynecol Obstet Invest; 2018; 83(1):45-51. PubMed ID: 28571024
[TBL] [Abstract][Full Text] [Related]
11. Use of tetranectin, CA-125 and CASA to predict residual tumor and survival at second- and third-look operations for ovarian cancer.
Høgdall CK; Høgdall EV; Hørding U; Toftager-Larsen K; Arends J; Nørgaard-Pedersen B; Clemmensen I
Acta Oncol; 1996; 35(1):63-9. PubMed ID: 8619942
[TBL] [Abstract][Full Text] [Related]
12. The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer.
Gadducci A; Ferdeghini M; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
Int J Gynecol Cancer; 2001; 11(4):277-82. PubMed ID: 11520365
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive relevance of CA-125 at primary surgery of ovarian cancer.
Mury D; Woelber L; Jung S; Eulenburg C; Choschzick M; Witzel I; Schwarz J; Jaenicke F; Mahner S
J Cancer Res Clin Oncol; 2011 Jul; 137(7):1131-7. PubMed ID: 21344262
[TBL] [Abstract][Full Text] [Related]
14. Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA-125 level.
Obeidat B; Latimer J; Crawford R
Gynecol Obstet Invest; 2004; 57(3):153-6. PubMed ID: 14726621
[TBL] [Abstract][Full Text] [Related]
15. Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA 125).
Gronlund B; Høgdall EV; Christensen IJ; Johansen JS; Nørgaard-Pedersen B; Engelholm SA; Høgdall C
Int J Biol Markers; 2006; 21(3):141-8. PubMed ID: 17013795
[TBL] [Abstract][Full Text] [Related]
16. A retrospective study of preoperative CA 125 levels in 82 patients with ovarian cancer.
Rossi AC; Di Vagno G; Cormio G; Cazzolla A; Stefanelli S; D'Elia E; Selvaggi L
Arch Gynecol Obstet; 2004 May; 269(4):263-5. PubMed ID: 14745561
[TBL] [Abstract][Full Text] [Related]
17. The prognostic factor for recurrence in advanced-stage high-grade serous ovarian cancer after complete clinical remission: a nested case-control study.
Wang Q; Zheng Y; Wang P; Zhang J; Liu H; Li Q; Yin R; Bian C; Peng H; Peng Z
J Ovarian Res; 2021 Dec; 14(1):179. PubMed ID: 34930386
[TBL] [Abstract][Full Text] [Related]
18. Oviductal glycoprotein (OVGP1, MUC9): a differentiation-based mucin present in serum of women with ovarian cancer.
Maines-Bandiera S; Woo MM; Borugian M; Molday LL; Hii T; Gilks B; Leung PC; Molday RS; Auersperg N
Int J Gynecol Cancer; 2010 Jan; 20(1):16-22. PubMed ID: 20130498
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of tumor-associated glycoprotein-72 and CA 125 serum markers in patients with gynecologic diseases.
Guadagni F; Marth C; Zeimet AG; Ferroni P; Spila A; Abbolito R; Roselli M; Greiner JW; Schlom J
Am J Obstet Gynecol; 1994 Nov; 171(5):1183-91. PubMed ID: 7977516
[TBL] [Abstract][Full Text] [Related]
20. Cancer-associated serum antigen level: a novel prognostic indicator for survival in patients with recurrent ovarian carcinoma.
Gronlund B; Dehn H; Høgdall CK; Engelholm SA; Jørgensen M; Nørgaard-Pedersen B; Høgdall EV
Int J Gynecol Cancer; 2005; 15(5):836-43. PubMed ID: 16174233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]